Device classification under EU MDR is one of those topics that feels technical, but it’s actually a business decision disguised as regulation.
Because your class determines:
– Whether you need a Notified Body (and how early you must engage)
– How heavy your clinical evidence burden will be
– How much QMS and technical documentation you’ll need
– Your timeline and budget to CE marking
If you’re new to MDR, read this first for the overall roadmap.
And if you’re still shaping your claims, this intended purpose article helps a lot (classification starts with words).
What ‘device class’ actually means
EU MDR class (I, IIa, IIb, III) is a proxy for risk. Higher class generally means:
– More scrutiny
– More evidence
– More formal processes
– Longer timelines
For startups, the key is not to ‘aim for Class I’. The key is to classify correctly early, so you don’t build the wrong evidence plan.
Step 1: Start with intended purpose (always)
Classification is not based on your technology. It’s based on intended purpose, including:
– Medical purpose (diagnosis, monitoring, treatment, prediction, etc.)
– Who uses it (HCP vs lay)
– Where it’s used (home vs clinical)
– What decisions it influences
– Duration of contact / invasiveness (for hardware)
If your intended purpose is fuzzy, your classification will be fuzzy—and that’s where projects drift.
Step 2: Use Annex VIII rules (and document your rationale)
EU MDR classification is defined in Annex VIII. Your job is to:
1. Identify the relevant rule(s)
2. Apply them to your intended purpose
3. Write a short, defensible rationale
Deliverable to create now: a 1–2 page ‘Classification Rationale’ that includes:
– Intended purpose summary
– Applied Annex VIII rule(s)
– Justification (why this rule fits)
– Resulting class
– Conformity assessment route (self-certification vs Notified Body)
The startup reality: most products are not Class I
Many early-stage teams assume they’re Class I because they’re ‘just software’ or ‘just a tool’.
In practice:
– Many SaMD products end up Class IIa or higher depending on clinical impact
– Many hardware products become IIa/IIb depending on invasiveness and duration
– If you influence diagnosis or therapy decisions, your class often increases
This is not bad news—it’s just planning information.
A quick classification mindset for mixed portfolios (software + hardware)
If you have both software and hardware, ask early:
– Is the software an accessory, a standalone device, or part of a system?
– Does the software drive the hardware’s function or clinical decisions?
– Are you placing them on the market as one product or separate products?
This affects how you structure your technical documentation and your conformity assessment strategy.
What changes your class most (common ‘levers’)
These are the phrases and product choices that often shift class upward:
– ‘diagnose’ / ‘detect’ / ‘predict’ a condition
– ‘recommend’ treatment or therapy
– ‘triage’ patients
– ‘alarm’ functions that require immediate action
– Closed-loop or automated control
– Use in vulnerable populations
– Long-term invasive contact (hardware)
If your product does any of these, you can still succeed—you just need the right evidence plan.
Notified Body: the timeline impact you must plan for
If your classification requires a Notified Body, treat that as a core roadmap item.
Practical startup guidance:
– Engage early once classification is reasonably stable
– Build your QMS and Tech Doc progressively (don’t wait for ‘final’)
– Plan for review lead times that can be measured in months (sometimes longer)
Common mistakes (and how to avoid them)
– Classifying too late: you build the wrong V&V and clinical plan.
– Over-claiming: your class and evidence burden inflate unnecessarily.
– No written rationale: you lose time when investors, partners, or auditors ask ‘why’.
– Ignoring system boundaries: software + hardware combinations can change the assessment route.
A simple ‘start here’ checklist (this week)
1. Freeze a draft intended purpose (one paragraph)
2. Identify likely Annex VIII rule(s)
3. Write a classification rationale (1–2 pages)
4. Decide: self-certification vs Notified Body
5. Map the evidence impact (clinical + V&V) at a high level
Want to pressure-test your classification in 60 minutes?
If you want a founder-friendly sanity check on likely class and what it means for timeline, evidence, and Notified Body strategy, book a free 60-minute MDR Strategy Call.
Book here: https://calendly.com/niko-mangold-consultants/30min